{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:13:07Z","timestamp":1769155987280,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science","award":["26462000"],"award-info":[{"award-number":["26462000"]}]},{"name":"Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science","award":["26461183"],"award-info":[{"award-number":["26461183"]}]},{"name":"Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science","award":["16K09598"],"award-info":[{"award-number":["16K09598"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3300-y","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T14:59:37Z","timestamp":1493737177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways"],"prefix":"10.1186","volume":"17","author":[{"given":"Kengo","family":"Shimazu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenzo","family":"Hiroshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Namiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"3300_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","volume":"366","author":"BW Robinson","year":"2005","unstructured":"Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397\u2013408.","journal-title":"Lancet"},{"key":"3300_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"3300_CR3","doi-asserted-by":"crossref","unstructured":"Tada Y, Suzuki T, Shimada H, Hiroshima K, Tatsumi K, Tagawa M. Molecular-targeted therapy for malignant mesothelioma. Pleura. 2015:1\u201311.","DOI":"10.1177\/2373997515600403"},{"key":"3300_CR4","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/onc.2012.181","volume":"32","author":"MA Pierotti","year":"2013","unstructured":"Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects. Oncogene. 2013;32:1475\u201387.","journal-title":"Oncogene"},{"key":"3300_CR5","first-page":"57","volume":"2","author":"J Kasznicki","year":"2014","unstructured":"Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2:57.","journal-title":"Ann Transl Med"},{"key":"3300_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5500\/wjt.v2.i5.74","volume":"2","author":"M Salvadori","year":"2012","unstructured":"Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant. 2012;2:74\u201383.","journal-title":"World J Transplant"},{"key":"3300_CR7","doi-asserted-by":"publisher","unstructured":"Houghton. Everolimus. Clin Cancer Res. 2010;16:1368\u201372.","DOI":"10.1158\/1078-0432.CCR-09-1314"},{"key":"3300_CR8","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1200\/JCO.2008.21.3033","volume":"27","author":"SL Ellard","year":"2009","unstructured":"Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent\/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27:4536\u201341.","journal-title":"J Clin Oncol"},{"key":"3300_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.lungcan.2012.02.022","volume":"77","author":"S Cedr\u00e9s","year":"2012","unstructured":"Cedr\u00e9s S, Montero MA, Martinez P, Martinez A, Rodr\u00edguez-Freixin\u00f3s V, Torrejon D, Gabaldon A, Salcedo M, Ramon Y, Cajal S, Felip E. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer. 2012;77:192\u20138.","journal-title":"Lung Cancer"},{"key":"3300_CR10","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/onc.2013.280","volume":"33","author":"Y Guo","year":"2014","unstructured":"Guo Y, Chirieac LR, Bueno R, Pass H, Wu W, Malinowska IA, Kwiatkowski DJ. Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene. 2014;33:3151\u201360.","journal-title":"Oncogene"},{"key":"3300_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","volume":"9","author":"BK Bitanihirwe","year":"2014","unstructured":"Bitanihirwe BK, Meerang M, Friess M, Soltermann A, Frischknecht L, Thies S, Felley-Bosco E, Tsao MS, Allo G, de Perrot M, Seifert B, Moch H, Stahel R, Weder W, Opitz I. PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol. 2014;9:239\u201347.","journal-title":"J Thorac Oncol"},{"key":"3300_CR12","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/cncr.22552","volume":"109","author":"AY Lee","year":"2007","unstructured":"Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer. 2007;109:1454\u201361.","journal-title":"Cancer"},{"key":"3300_CR13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1073\/pnas.0507493103","volume":"103","author":"C Tovar","year":"2006","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006;103:1888\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3300_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018588","volume":"6","author":"R Villalonga-Planells","year":"2011","unstructured":"Villalonga-Planells R, Coll-Mulet L, Mart\u00ednez-Soler F, Casta\u00f1o E, Acebes JJ, Gim\u00e9nez-Bonaf\u00e9 P, Gil J, Tortosa A. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One. 2011;6:e18588.","journal-title":"PLoS One"},{"key":"3300_CR15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1158\/1078-0432.CCR-10-1587","volume":"17","author":"KI Pishas","year":"2011","unstructured":"Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF, Neilsen PM. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res. 2011;17:494\u2013504.","journal-title":"Clin Cancer Res"},{"key":"3300_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/cgt.2011.86","volume":"19","author":"Q Li","year":"2012","unstructured":"Li Q, Kawamura K, Okamoto S, Yamanaka M, Yang S, Yamauchi S, Fukamachi T, Kobayashi H, Tada Y, Takiguchi Y, Tatsumi K, Shimada H, Hiroshima K, Tagawa M. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther. 2012;19:218\u201328.","journal-title":"Cancer Gene Ther"},{"key":"3300_CR17","doi-asserted-by":"publisher","first-page":"8204","DOI":"10.1073\/pnas.0502857102","volume":"102","author":"Z Feng","year":"2005","unstructured":"Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A. 2005;102:8204\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3300_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.molcel.2005.03.027","volume":"18","author":"RG Jones","year":"2005","unstructured":"Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell. 2005;18:283\u201393.","journal-title":"Mol Cell"},{"key":"3300_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.cell.2008.06.028","volume":"134","author":"AV Budanov","year":"2008","unstructured":"Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008;134:451\u201360.","journal-title":"Cell"},{"key":"3300_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.18632\/oncotarget.248","volume":"2","author":"P Apontes","year":"2011","unstructured":"Apontes P, Leontieva OV, Demidenko ZN, Li F, Blagosklonny MV. Exploring long-term protection of normal human fibroblasts and epithelial cells from chemotherapy in cell culture. Oncotarget. 2011;2:222\u201333.","journal-title":"Oncotarget"},{"key":"3300_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1349-7006.2006.00163.x","volume":"97","author":"E Nakataki","year":"2006","unstructured":"Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 2006;97:183\u201391.","journal-title":"Cancer Sci"},{"key":"3300_CR22","first-page":"979","volume":"134","author":"Y Ke","year":"1989","unstructured":"Ke Y, Reddel RR, Gerwin BI, Reddel HK, Somers AN, McMenamin MG, LaVeck MA, Stahel RA, Lechner JF, Harris CC. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am J Pathol. 1989;134:979\u201391.","journal-title":"Am J Pathol"},{"key":"3300_CR23","doi-asserted-by":"publisher","unstructured":"Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, Mattioli E, Iannuzzi CA, Budillon A, Giordano A, Pentimalli F. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13:652-665","DOI":"10.4161\/cc.27546"},{"key":"3300_CR24","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","volume":"71","author":"I Ben Sahra","year":"2011","unstructured":"Ben Sahra I, Regazzetti C, Robert G, Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF, Giorgetti-Peraldi S, Bost F. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res. 2011;71:4366\u201372.","journal-title":"Cancer Res"},{"key":"3300_CR25","doi-asserted-by":"publisher","first-page":"e1088","DOI":"10.1038\/cddis.2014.59","volume":"5","author":"Y Feng","year":"2014","unstructured":"Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, SC-J Y, Zhang H. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5:e1088.","journal-title":"Cell Death Dis"},{"key":"3300_CR26","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4161\/cc.10.7.15210","volume":"10","author":"C Oliveras-Ferraros","year":"2011","unstructured":"Oliveras-Ferraros C, Cuf\u00ed S, Vazquez-Martin A, Torres-Garcia VZ, Del Barco S, Martin-Castillo B, Menendez JA. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGF\u03b2-induced oncomiR miRNA-181a. Cell Cycle. 2011;10:1144\u201351.","journal-title":"Cell Cycle"},{"key":"3300_CR27","doi-asserted-by":"publisher","first-page":"e0139254","DOI":"10.1371\/journal.pone.0139254","volume":"10","author":"G Borthakur","year":"2015","unstructured":"Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. PLoS One. 2015;10:e0139254.","journal-title":"PLoS One"},{"key":"3300_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1093\/carcin\/bgt166","volume":"34","author":"Y Sekido","year":"2013","unstructured":"Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013;34:1413\u20139.","journal-title":"Carcinogenesis"},{"key":"3300_CR29","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/cas.12227","volume":"104","author":"M Nishio","year":"2013","unstructured":"Nishio M, Otsubo K, Maehama T, Mimori K, Suzuki A. Capturing the mammalian Hippo: elucidating its role in cancer. Cancer Sci. 2013;104:1271\u20137.","journal-title":"Cancer Sci"},{"key":"3300_CR30","doi-asserted-by":"publisher","first-page":"10073","DOI":"10.18632\/oncotarget.3543","volume":"6","author":"JH Cho","year":"2015","unstructured":"Cho JH, Lee SJ, Oh AY, Yoon MH, Woo TG, Park BJ. NF2 blocks Snail-mediated p53 suppression in mesothelioma. Oncotarget. 2015;6:10073\u201385.","journal-title":"Oncotarget"},{"key":"3300_CR31","doi-asserted-by":"publisher","first-page":"a001057","DOI":"10.1101\/cshperspect.a001057","volume":"2","author":"Z Feng","year":"2010","unstructured":"Feng Z. p53 regulation of the IGF-1\/AKT\/mTOR pathways and the endosomal compartment. Cold Spring Harb Perspect Biol. 2010;2:a001057.","journal-title":"Cold Spring Harb Perspect Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T21:42:16Z","timestamp":1569188536000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3300-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3300"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3300-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]},"article-number":"309"}}